GLP-1RA and SGLT2 inhibitor combination therapy was associated with better cardiorenal outcomes than monotherapy among patients with type 2 diabetes. The cardiorenal benefits of sodium-glucose ...
According to Lexicon, Inpefa (sotagliflozin) will continue to be manufactured and made available to patients. The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to ...